Phaseline

Companies › NEOK Bio

NEOK Bio: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NEOK001
B7-H3 and ROR1 targeting bispecific antibody-drug conjugate
B7H3, ROR1Phase 1Locally Advanced (Unresectable) or Metastatic Solid TumorsJan 2029
NEOK002
EGFR and MUC1-targeting bispecific antibody-drug conjugate (ADC)
EGFR, MUC1Phase 1Locally Advanced (Unresectable) or Metastatic Solid TumorsFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07612176NEOK001Phase 1Locally Advanced (Unresectable) or Metastatic Solid TumorsOncologyJan 2029
NCT07612189NEOK002Phase 1Locally Advanced (Unresectable) or Metastatic Solid TumorsOncologyFeb 2029

Targets

EGFR (1) MUC1 (1) B7H3 (1) ROR1 (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Dizal Pharmaceuticals Betta Pharmaceuticals Beijing Biotech Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Shanghai JMT-Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.